Liquidia Corporation (LQDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Liquidia is a biopharmaceutical company focused on improving inhaled drug delivery through proprietary formulations, particularly in the prostacyclin class of therapeutics [4]. Performance Highlights - The company had a spectacular year in 2025, indicating strong performance and growth [2]. Leadership Team - The presentation included key members of the leadership team, such as the CEO Roger Jeffs, CFO Michael Kaseta, and other executives, highlighting the collaborative effort in driving the company's vision [3].